γ-secretases: from cell biology to therapeutic strategies

被引:138
作者
Bergmans, Bruno A. [1 ,2 ]
De Strooper, Bart [1 ,2 ]
机构
[1] Katholieke Univ Leuven, Ctr Human Genet, B-3000 Leuven, Belgium
[2] VIB, Dept Mol & Dev Genet, Leuven, Belgium
关键词
FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; AGE-OF-ONSET; RANDOMIZED CONTROLLED-TRIAL; GENOME-WIDE ASSOCIATION; COTTON WOOL PLAQUES; SPASTIC PARAPARESIS; PRESENILIN-1; MUTATION; IN-VIVO;
D O I
10.1016/S1474-4422(09)70332-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Presenilins form the catalytic part of the gamma-secretases, protein complexes that are responsible for the intramembranous cleavage of transmembrane proteins. The presenilins are involved in several biological functions, but are best known for their role in the generation of the beta-amyloid (A beta) peptide in Alzheimer's disease and are therefore thought to be important drug targets for this disorder. Mutations in the presenilin genes cause early-onset familial Alzheimer's disease, but mutation carriers have substantial phenotypic heterogeneity. Recent evidence implicating presenilin mutations in non-Alzheimer's dementias, including frontotemporal dementia and Lewy body dementia, warrants further investigation. An increased understanding of the diversity of the molecular cell biology of the gamma-secretase complex and the effects of clinical mutations in the presenilin genes might help pave the way for improved development of drugs that are designed to target gamma-secretase enzymatic activity in Alzheimer's disease and potentially in other neurological diseases.
引用
收藏
页码:215 / 226
页数:12
相关论文
共 171 条
  • [1] Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial
    Aisen, PS
    Schafer, KA
    Grundman, M
    Pfeiffer, E
    Sano, M
    Davis, KL
    Farlow, MR
    Jin, S
    Thomas, RG
    Thal, LJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21): : 2819 - 2826
  • [2] *ALZH RES FOR, PRES 1 MUT
  • [3] *ALZH RES FOR, 2009, PRES MUT DIR
  • [4] A presenilin 1 mutation associated with familial frontotemporal dementia inhibits γ-secretase cleavage of APP and notch
    Amtul, Z
    Lewis, PA
    Piper, S
    Crook, R
    Baker, M
    Findlay, K
    Singleton, A
    Hogg, M
    Younkin, L
    Younkin, SG
    Hardy, J
    Hutton, M
    Boeve, BF
    Tang-Wai, D
    Golde, TE
    [J]. NEUROBIOLOGY OF DISEASE, 2002, 9 (02) : 269 - 273
  • [5] [Anonymous], A phase 2 multicenter, ran-domized, double-masked, sham-controlled study of the safetyand efficacy of intravitreal injections of NGM621 in subjects with geographic atrophy (GA) Secondary to age-related mac-ular degeneration (AMD)
  • [6] [Anonymous], 2002, Cochrane Database Systematic Review
  • [7] Gamma secretase-mediated notch signaling worsens brain damage and functional outcome in ischemic stroke
    Arumugam, TV
    Chan, SL
    Jo, DG
    Yilmaz, G
    Tang, SC
    Cheng, AW
    Gleichmann, M
    Okun, E
    Dixit, VD
    Chigurupati, S
    Mughal, MR
    Ouyang, X
    Miele, L
    Magnus, T
    Poosala, S
    Granger, DN
    Mattson, MP
    [J]. NATURE MEDICINE, 2006, 12 (06) : 621 - 623
  • [8] Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation
    Assini, A
    Terreni, L
    Borghi, R
    Giliberto, L
    Piccini, A
    Loqui, D
    Fogliarino, S
    Forloni, G
    Tabaton, M
    [J]. NEUROLOGY, 2003, 60 (01) : 150 - 151
  • [9] A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis
    Ataka, S
    Tomiyama, T
    Takuma, H
    Yamashita, T
    Shimada, H
    Tsutada, T
    Kawabata, K
    Mori, H
    Miki, T
    [J]. ARCHIVES OF NEUROLOGY, 2004, 61 (11) : 1773 - 1776
  • [10] ATSUSHI I, 2005, ANN NEUROL, V57, P429